GFM
NVCR icon

GF Fund Management’s NovoCure NVCR Stock Holding History

GF Fund Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.3K Buy
2,501
+302
+14% +$3.77K ﹤0.01% 466
2025
Q4 		$28.4K Sell
2,199
-206
-9% -$2.64K ﹤0.01% 469
2025
Q3 		$31.1K Sell
2,405
-365
-13% -$4.88K ﹤0.01% 440
2025
Q2 		$49.3K Hold
2,770
– – ﹤0.01% 416
2025
Q1 		$49.4K Buy
2,770
+498
+22% +$11.3K ﹤0.01% 422
2024
Q4 		$67.7K Buy
+2,272
New +$48.1K ﹤0.01% 362

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

GF Fund Management's NVCR Position: Q1 2026 in Review

GF Fund Management increased its NovoCure (NVCR) stake by 14% in Q1 2026, buying an estimated $3.77K and bringing the position to 2,501 shares worth $27.3K. The position accounts for ﹤0.01% of the portfolio, ranked #466.

GF Fund Management first reported a position in NVCR in Q4 2024 and has held it in 6 quarters since. The position peaked at $67.7K in Q4 2024. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • GF Fund Management held 2,501 shares of NovoCure worth $27.3K as of Q1 2026.
  • GF Fund Management bought 302 NovoCure shares in Q1 2026, an estimated $3.77K.
  • NovoCure made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #466 holding.
  • GF Fund Management first reported a position in NovoCure in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's NovoCure position peaked at $67.7K in Q4 2024.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.